Bristol Myers Squibb (BMS) has reported positive interim Phase III EXCALIBER-RRMM results showing iberdomide combined with daratumumab and dexamethasone significantly improved minimal residual disease (MRD) negativity rates versus active comparator daratumumab plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma (r/r MM). The cereblon E3 ligase modulator (CELMoD) met one co-primary endpoint with the data monitoring committee recommending continuation to assess progression-free survival (PFS) and overall survival (OS) endpoints. Safety profiles remained consistent with previous studies supporting potential registration pathway for the novel mechanism in heavily pretreated patients.

The randomised open-label trial enrolled 664 patients across two stages with 1.0 mg iberdomide identified as optimal dose based on safety, pharmacokinetics and efficacy data. Secondary endpoints include overall response rate, duration of response, time to progression, time to next treatment and health-related quality of life measures. Iberdomide represents a next-generation immunomodulatory drug building on the proteolysis-targeting chimera (PROTAC) platform with enhanced target degradation efficiency over first-generation cereblon modulators.

PharmCube's NextBiopharm® database shows that MM is the most advanced indication among the eight that iberdomide is being developed in. Click here to request a free trial for NextBiopharm®.

Source: 药明康德